Supplemental Table 10. Association between aging constructs and mortality among cancer survivors<sup>a</sup> and controls<sup>a</sup>; putting eight aging constructs in a single model, HRS (2016-2020)

Cancer survivors $(N = 410)$	
Aging constructs	HR (95% CI) <sup>b</sup> per 1 SD for aging constructs
KDM-BA-Accel	1.24 (0.83, 1.86)
PhenoAgeAccel	1.34 (0.97, 1.85)
SA-Accel	0.88 (0.51, 1.52)
HannumAccel	1.15 (0.86, 1.47)
HorvathAccel	1.16 (0.86, 1.56)
LevineAccel	1.41 (1.07, 1.87)
GrimAgeAccel	1.96 (1.09, 3.53)
POA	0.77 (0.50, 1.21)
Controls $(N = 2003)$	
Aging constructs	HR (95% CI) <sup>b</sup> per 1 SD for aging constructs
KDM-BA-Accel	1.07 (1.02, 1.13)
PhenoAgeAccel	1.01 (0.98, 1.04)
SA-Accel	1.01 (0.97, 1.04)
HannumAccel	1.01 (0.95, 1.07)
HorvathAccel	1.01 (0.95, 1.07)
LevineAccel	1.04 (0.99, 1.09)
GrimAgeAccel	1.02 (0.95, 1.08)
POA	6.49 (0.81, 52.53)

<sup>&</sup>lt;sup>a</sup>Cancer survivors and controls who were in both Sample A and Sample B had data on all aging constructs. <sup>b</sup>The model was adjusted for chronological age, race/ethnicity, BMI, smoking status, comorbidity index, and CMV infection.